丰倍生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	1.9B	1.7B	1.7B	1.3B	790.0M
Revenue Growth %	12.7%	1.1%	31.9%	64.1%	--
Total Revenue	1.9B	1.7B	1.7B	1.3B	790.0M
Cost Of Revenue	1.7B	1.5B	1.5B	1.1B	675.0M
+Gross Profit	227.0M	241.0M	232.0M	196.0M	115.0M
Gross Margin %	11.7%	13.9%	13.6%	15.1%	14.6%
Total Operating Cost	1.8B	1.6B	1.6B	1.2B	736.0M
Selling Expenses	21.8M	21.8M	15.7M	13.7M	7.0M
Admin Expenses	29.1M	35.1M	25.4M	22.5M	17.0M
Rd Expenses	53.6M	58.6M	51.3M	41.9M	25.2M
Finance Expenses	1.2M	2.3M	-3.6M	5.6M	7.1M
+Operating Income	131.0M	143.0M	146.0M	119.0M	58.1M
Operating Margin %	6.7%	8.3%	8.5%	9.2%	7.4%
Non Operating Income	3.2M	2.3M	113,200	93,400	1.2M
Non Operating Expenses	127,900	1.0M	3.0M	10.6M	600,300
Investment Income	290,200	-3.4M	-5.4M	2.2M	-423,800
Fair Value Change Income	-340,700	-577,800	412,500	-717,500	859,500
Asset Disposal Income	48,800	20,500	-63,600	-409,100	--
Asset Impairment Loss	734,600	1.4M	1.3M	368,600	418,500
Other Income	20.3M	33.2M	18.0M	15.4M	3.4M
Income Before Tax	134.0M	144.0M	143.0M	108.0M	58.7M
Income Tax	10.6M	14.7M	10.1M	6.4M	9.0M
+Net Income	124.0M	130.0M	133.0M	102.0M	49.7M
Net Margin %	6.4%	7.5%	7.8%	7.9%	6.3%
Net Income Attributable	124.0M	130.0M	133.0M	102.0M	49.0M
Minority Interest	--	--	1,900	123,300	690,000
Eps Basic	1.15	1.21	1.26	0.96	0.49
Eps Diluted	1.15	1.21	1.26	0.96	0.49

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	167.0M	157.0M	218.0M	84.5M	37.9M
Trading Financial Assets	--	--	834,000	177,500	859,500
Accounts Receivable	133.0M	58.5M	96.8M	85.8M	61.6M
Notes Receivable	62.9M	45.2M	41.7M	46.7M	45.4M
Notes And Accounts Receivable	196.0M	104.0M	138.0M	132.0M	107.0M
Prepayments	34.5M	14.6M	85.4M	37.9M	28.5M
Inventory	242.0M	198.0M	104.0M	118.0M	129.0M
Total Current Assets	730.0M	568.0M	613.0M	422.0M	340.0M
Fixed Assets	--	140.0M	88.2M	86.7M	61.5M
Fixed Assets Total	134.0M	140.0M	88.2M	86.7M	61.5M
Construction In Progress	--	261.0M	155.0M	27.8M	16.6M
Construction In Progress Total	292.0M	263.0M	156.0M	27.8M	16.6M
Intangible Assets	59.8M	61.1M	50.8M	52.0M	9.1M
Long Term Deferred Expenses	2.6M	3.9M	4.6M	3.7M	--
Total Non Current Assets	507.0M	483.0M	325.0M	177.0M	88.9M
Total Assets	1.2B	1.1B	938.0M	599.0M	429.0M
Short Term Borrowings	173.0M	142.0M	159.0M	100.0M	58.6M
Accounts Payable	75.3M	88.0M	57.4M	23.3M	24.3M
Contract Liabilities	27.4M	30.4M	35.3M	20.3M	27.1M
Total Current Liabilities	359.0M	337.0M	373.0M	213.0M	145.0M
Long Term Borrowings	106.0M	72.9M	40.5M	--	--
Total Non Current Liabilities	122.0M	85.3M	51.3M	3.6M	3.3M
Total Liabilities	481.0M	422.0M	424.0M	217.0M	149.0M
Paid In Capital	108.0M	108.0M	108.0M	106.0M	106.0M
Capital Reserve	190.0M	187.0M	185.0M	87.3M	87.3M
Surplus Reserve	26.9M	14.1M	8.8M	8.3M	4.2M
Retained Earnings	432.0M	321.0M	212.0M	179.0M	81.6M
Minority Equity	--	--	--	1.5M	1.4M
Equity Attributable	756.0M	630.0M	513.0M	381.0M	279.0M
Total Equity	756.0M	630.0M	513.0M	382.0M	280.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	2.0B	1.9B	1.9B	1.3B	797.0M
Tax Refunds Received	48.3M	27.9M	24.9M	16.6M	18.5M
Total Operating Cash Inflow	2.1B	2.0B	1.9B	1.4B	819.0M
Cash Paid For Goods	1.9B	1.7B	1.7B	1.2B	678.0M
Cash Paid To Employees	54.8M	47.5M	40.2M	34.3M	26.8M
Taxes Paid	37.9M	76.7M	68.2M	58.2M	26.7M
Total Operating Cash Outflow	2.1B	1.9B	1.9B	1.3B	744.0M
Operating Cash Flow	22.4M	162.0M	69.7M	77.0M	74.9M
Total Investing Cash Inflow	7.7M	93.8M	52.2M	208.0M	35.5M
Total Investing Cash Outflow	86.6M	261.0M	139.0M	281.0M	50.7M
Investing Cash Flow	-78.9M	-167.0M	-87.1M	-72.4M	-15.2M
Cash From Borrowings	315.0M	249.0M	329.0M	165.0M	102.0M
Dividends And Interest Paid	10.6M	25.4M	22.0M	3.9M	3.3M
Debt Repayments	243.0M	245.0M	219.0M	125.0M	105.0M
Total Financing Cash Inflow	323.0M	249.0M	343.0M	165.0M	129.0M
Total Financing Cash Outflow	258.0M	276.0M	245.0M	129.0M	163.0M
Financing Cash Flow	64.9M	-26.2M	98.0M	35.8M	-33.9M
Net Change In Cash	13.1M	-28.2M	90.9M	38.5M	23.4M
Ending Cash Balance	151.0M	138.0M	166.0M	75.0M	36.5M
Capex	79.5M	168.0M	80.1M	71.9M	16.0M